About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Experience and Results From an Academic Medical Center
One institution's review of 17 drug classes led to 3 formulary additions, 15 deletions, 5 new therapeutic interchanges, and 6 drug-safety issues requiring action. Cost-savings opportunities also resulted from using generic medications and alternative product formulations.
Emily L. Persson, PharmD, BCPS; Katherine S. Miller, PharmD, BCPS; Jennifer A. Nieman, PharmD, BCPS; Angela P. Sgourakis, PharmD; and Shawn R. Akkerman, PharmD
Current treatment of herpes zoster includes antiviral agents and analgesic drugs, but no single drug or combination can prevent or completely relieve symptoms. VZV vaccinations can help to reduce health and economic effects of the virus.
Kenneth R. Cohen, PharmD, PhD, CGP; Rebecca L. Salbu, PharmD, CGP; Jerry Frank, MD, FAAFP; and Igor Israel, MD
Keeping Patients Enrolled
In 2007, there were no medical applications (apps) for mobile devices, but within
3 years, 44 million mobile apps had been downloaded onto electronic devices.
This article reviews pingmd and Cancer.Net.
Michele B. Kaufman, PharmD, RPh
Matthew Grissinger, RPh, FASCP
Health Plans and PBMs Block Broader Drug Access For Patients and Businesses
Patients and small businesses might not be able to obtain some brand-name drugs when the new health exchanges are in place.
FDA approvals, drug indications, and updates
Oxybutynin Transdermal System (Oxytrol for Women) for overactive bladder; alogliptin tablets (Nesina, Kazano, and Oseni) for diabetes; and pomalidomide (Pomalyst) capsules for multiple myeloma
Marvin M. Goldenberg, PhD, RPh, MS
Apixaban (Eliquis) for treating and preventing thrombo-embolic disease
Aliaksandr Budovich; Olga Zargarova; and Anna Nogid, BS, PharmD, BCPS